[1]曹耿飞,纪卫政,顾俊鹏,等.贝伐单抗联合TACE治疗TACE 抵抗性肝癌13例疗效观察[J].介入放射学杂志,2015,(01):69-73.
　CAO Geng fei,JI Wei zheng,GU Jun peng,et al.Transarterial infusion of bevacizumab combined with TACE for the treatment of TACE refractory HCC： therapeutic analysis of 13 cases[J].journal interventional radiology,2015,(01):69-73.
点击复制

贝伐单抗联合TACE治疗TACE 抵抗性肝癌13例疗效观察 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2015年01期
页码:
69-73
栏目:
临床研究
出版日期:
2015-01-25

文章信息/Info

Title:
Transarterial infusion of bevacizumab combined with TACE for the treatment of TACE refractory HCC： therapeutic analysis of 13 cases
作者:
曹耿飞;  纪卫政;  顾俊鹏;  朱帝文;  张海潇;  任伟新
Author(s):
CAO Geng fei;  JI Wei zheng;  GU Jun peng;  ZHU Di wen;  ZHANG Hai xiao;  REN Wei xin.
Department of Interventional Radiology， First Affiliated Hospital， Xinjiang Medical University， Urumqi， the Xinjiang Uygur Autonomous Region 830054， China
关键词:
【关键词】 肝癌;  贝伐单抗;  TACE;  TACE 抵抗
文献标志码:
A
摘要:
【摘要】 目的 探讨经导管灌注贝伐单抗联合肝动脉化疗栓塞术（TACE），治疗TACE 抵抗性肝细胞肝癌的安全性及有效性。方法 2012年10月—2013年9月，行介入治疗的584例肝细胞肝癌患者中，13例患者出现TACE 抵抗，并行经导管灌注贝伐单抗联合TACE。术后依据mRCIST标准评价肿瘤反应，观察患者体能评分、肝功能改善情况，以及患者无疾病生存期和总生存期。结果 13例患者中PR 2例，SD 8例，PD 3例。ECOG评分改善者6例，肝功能改善者6例，中位无疾病进展生存期为356.5 d，中位生存期410.0 d；无治疗相关性死亡及严重并发症。结论 经导管灌注贝伐单抗联合TACE，在治疗TACE 抵抗性肝癌中疗效肯定，方法安全。

参考文献/References:

［1］ Takayasu K， Arii S， Ikai I， et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8 510 patients［J］. Gastroenterology， 2006， 131： 461 469.
［2］ Seki A， Hori S. Switching the loaded agent from epirubicin to cisplatin： salvage transcatheter arterial chemoembolization with drug eluting microspheres for unresectable hepatocellular carcinoma［J］. Cardiovasc Intervent Radiol， 2012， 35： 555 562.
［3］ Poon RT， Ho JW， Tong CS， et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma［J］. Br J Surg， 2004， 91： 1354 1360.
［4］ Yamanaka K， Hatano E， Kitamura K， et al. Early evaluation of transcatheter arterial chemoembolization refractory hepatocellular carcinoma［J］. J Gastroenterol， 2012， 47： 343 346.
［5］ Bruix J， Sherman M. Management of hepatoceullular carcinoma［J］. Hepatology， 2005， 42： 1208 1236.
［6］ Llovet JM， Real MI， Monta?觡a X， et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma： a randomised controlled trial［J］. Lancet， 2002， 359 ： 1734 1739.
［7］ Wang， B， Xu H， Gao ZQ， et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization［J］. Acta Radiol， 2008， 49： 523 529.
［8］ Finn RS， Zhu AX. Targeting angiogenesis in hepatocellular carcinoma： focus on VEGF and bevacizumab［J］. Expert Rev Anticancer Ther， 2009， 9： 503 509.
［9］ Chao Y， Li CP， Chau GY， et al. Prognostic significance of vascular endothelial growth factor， basic fibroblast growth factor， and angiogenin in patients with resectable hepatocellular carcinoma after surgery ［J］. Ann Surg Oncol， 2003， 10： 355 362.
［10］ Poon RT， Ng IO， Lau C， et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma： a prospective study［J］. Ann Surg， 2001， 233： 227 235.
［11］ 管清龙， 任伟新， 纪卫政. 肝癌治疗后血清内血管内皮生长因子对预后影响的研究进展［J］． 介入放射学杂志， 2013， 22： 701 704．
［12］ Li X， Feng， GS， Zheng CS， et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level ［J］. World J Gastroenterol， 2004， 10： 2878 2882.
［13］ Kim YH， Park JW， Joo J， et al. Severity and timing of progression predict refractoriness to transarterial chemoemboliz ation in hepatocellular carcinoma［J］. J Gastroenterol Hepatol， 2012， 27： 1051 1056.
［14］ Kabbinavar FF， Schulz J， McCleod M， et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first line metastatic colorectal cancer： results of a randomized phase II trial［J］. J Clin Oncol， 2005， 23： 3697 3705.
［15］ Rubbia Brandt L， Lauwers GY， Wang H， et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis［J］. Histopathology， 2010， 56： 430 439.
［16］ Britten CD， Gomes AS， Wainberg ZA， et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer： a pilot study［J］. BMC Cancer， 2012， 12： 16.
［17］ Ren JJ， Jiang T， Peng R. Adverse reaction of a combined treatment for unresectable liver cancer［J］. Cent Eur J Med， 2014， 9： 272 278.
［18］ Bolondi L， Burroughs A， Dufour JF， et al. Heterogeneity of patients with intermediate（BCLC B） Hepatocellular Carcinoma：proposal for a subclassification to facilitate treatment decisions［J］. Semin Liver Dis， 2012， 32： 348 359.
［19］ Deleve LD， Wang X， Tsai J， et al. Sinusoidal obstruction syndrome （veno occlusive disease） in the rat is prevented by matrix metalloproteinase inhibition ［J］. Gastroenterology， 2003， 125： 882 890.

相似文献/References:

[1]张　　　磊,陆骊工,李　　　勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,(12):968.
　ZHANG Lei,LU Li-gong,LI Yong,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].journal interventional radiology,2011,(01):968.
[2]敖 劲,张跃伟,徐 克. 明胶海绵微粒经动脉栓塞治疗原发性肝癌的研究现状[J].介入放射学杂志,2011,(12):1010.
　AO Jin,ZHANG Yue-wei,XU Ke..Gelatin sponge particle used as an embolic agent in transcatheter arterial chemoembolization treatment for primary hepatocellular carcinoma: its current situation in research[J].journal interventional radiology,2011,(01):1010.
[3]杜丹丹,吕维富. 肝癌射频消融后的影像学评价[J].介入放射学杂志,2012,(01):75.
　DU Dan dan,Lv Wei fu..Imaging evaluation of liver cancer after radiofrequency ablation therapy[J].journal interventional radiology,2012,(01):75.
[4]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(01):78.
[5]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(01):322.
[6]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].journal interventional radiology,2012,(01):348.
[7]何海涛,刘 圣,刘建秦,等. 肝癌TACE术并发脑碘油栓塞二例并文献复习[J].介入放射学杂志,2012,(08):682.
　HE Hai- tao,LIU sheng,LIU Jian- qing,et al. Cerebral Lipiodol embolism occurred after transcatheter arterial chemoembolization for hepatocellular carcinoma: report of two cases with literature review[J].journal interventional radiology,2012,(01):682.
[8]冉 琳,任伯绪. 125I粒子组织间近距离放射治疗肝癌的现状与进展[J].介入放射学杂志,2012,(10):876.
　RAN Lin,REN Bo- xu.. 125I radioactive seeds brachytherapy for hepatocellular carcinomas： its present situation and research progress[J].journal interventional radiology,2012,(01):876.
[9]罗中华,秦 勉,张学昕,等.原发性肝癌合并下腔静脉及右心房癌栓的动脉内化疗栓塞治疗[J].介入放射学杂志,2012,(12):1035.
　LUO Zhong? hua,QIN Mian,ZHANG Xue? xin,et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by tumor thrombus in inferior vena cava and right atrium[J].journal interventional radiology,2012,(01):1035.
[10]徐光如,张明辉,朱红星,等.磁共振ADC值评价肝硬化合并肝癌介入治疗后肝功能储备的初步研究[J].介入放射学杂志,2013,(01):36.
　XU Guang? ru,ZHANG Ming? hui,ZHU Hong? xing,et al. The application of MR?蛳 ADC value in evaluating the liver function reserve in patients with cirrhosis complicated by hepatic cancer after interventional treatment： a preliminary study[J].journal interventional radiology,2013,(01):36.

备注/Memo

备注/Memo:
（收稿日期：２０１4-０5-23）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2015-01-26